molnupiravir

Also known as MK-4482, EIDD-2801, [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl-2-methylpropanoate, uridine, 4-oxime, 5′-(2-methylpropanoate)

Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID19 in those infected by SARS-CoV-2. It is taken by mouth.

Key facts

Drug.H: 19
Drug.N: 3
Drug.O: 7
Drug.C: 13
Drug.image: MK-4482.svg
Drug.image_class: skin-invert-image
Drug.tradename: Lagevrio
Drug.MedlinePlus: a622027
Drug.DailyMedID: Molnupiravir
Drug.pregnancy_AU: D
Drug.pregnancy_category: Not recommended
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: J05
Drug.ATC_suffix: AB18
Drug.legal_AU: S4
Drug.legal_BR: C1
Drug.legal_UK: POM
Drug.legal_US: Rx-only

via Wikipedia infobox

Chemical data

Formula: C13H19N3O7
Molecular weight: 329.31 g/mol
IUPAC name: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate
SMILES: CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)NO)O)O
InChIKey: HTNPEHXGEKVIHG-QCNRFFRDSA-N
XLogP: -0.8
Polar surface area: 141 Å²
H-bond donors: 4
H-bond acceptors: 7
Formal charge: 0

via PubChem

~11 min read

Encyclopedic overview

17 sections

Contents

Medical uses
Contraindications
Adverse effects
Overdose
Drug interactions
Mechanism of action
Chemistry
History
Society and culture
Economics
Legal status
Brand names
Public health concerns
Research
References
Further reading
External links

Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action by introducing copying errors during viral RNA replication.

Excerpted from Wikipedia’s “molnupiravir” article, available under the CC BY-SA 4.0 licence.